Scholarlink

<p>Circulating tumor DNA (ctDNA) variants hold significant promise as cancer biomarkers in liquid biopsies, owing to their minimally invasive testing approach and capacity to capture the comprehensive tumor landscape. However, a comprehensive resource for studying ctDNA variants is still lacking. Here, we developed CTDdgv to systematically identify ctDNA variants and interpret their clinical relevance. We manually curated 1674 experimentally validated clinical interpretations for ctDNA variants, concerning prognosis, drug resistance, tumor characteristics, metastasis monitoring, therapy, prospect for detection, and others. Furthermore, we developed and integrated a pipeline that identifies tumor driver genes (TDGs) and variants (TDVs) and evaluates the prognostic significance of potential TDGs. Using publicly available ctDNA mutation spectra, we identified potential TDGs and TDVs from 38 datasets across 17 cancer types. Based on these datasets, we provide a multi-dimensional analysis of TDG gene sets in specific cancer types, providing insights into their driving effects. Collectively, CTDdgv has significant potential to serve as a valuable resource for molecular diagnostics and therapeutic decision-making in cancer via liquid biopsy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月16日

查看全文
  • Yuncong Wang,
  • Jing Gan,
  • Haoyu Hu,
  • Manyi Xu,
  • Yongle Xu,
  • Yusen Zhao,
  • Wenbo Dong,
  • Xinrong Li,
  • Hongbo Zhu,
  • Shuangshuang Wang,
  • Jiaheng He,
  • Shangwei Ning,
  • Peng Wang,
  • Hui Zhi

摘要

Circulating tumor DNA (ctDNA) variants hold significant promise as cancer biomarkers in liquid biopsies, owing to their minimally invasive testing approach and capacity to capture the comprehensive tumor landscape. However, a comprehensive resource for studying ctDNA variants is still lacking. Here, we developed CTDdgv to systematically identify ctDNA variants and interpret their clinical relevance. We manually curated 1674 experimentally validated clinical interpretations for ctDNA variants, concerning prognosis, drug resistance, tumor characteristics, metastasis monitoring, therapy, prospect for detection, and others. Furthermore, we developed and integrated a pipeline that identifies tumor driver genes (TDGs) and variants (TDVs) and evaluates the prognostic significance of potential TDGs. Using publicly available ctDNA mutation spectra, we identified potential TDGs and TDVs from 38 datasets across 17 cancer types. Based on these datasets, we provide a multi-dimensional analysis of TDG gene sets in specific cancer types, providing insights into their driving effects. Collectively, CTDdgv has significant potential to serve as a valuable resource for molecular diagnostics and therapeutic decision-making in cancer via liquid biopsy.